Compare General Motors Company (GM) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs Merck & Co., Inc. — how do they compare? General Motors Company trades at $82.75 (market cap $72.17B), while Merck & Co., Inc. trades at $142.58 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 4.9× General Motors Company's market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold General Motors Company for 83 Days and Merck & Co., Inc. for 98 Days on average.
| GM | MRK | |
|---|---|---|
Market Cap | $72.17B | $351.28B |
Volume | 4,900,304 | 7,969,665 |
Sector | Consumer Cyclical | Health |
52-Week High | $90.30 | $156.43 |
52-Week Low | $55.35 | $82.49 |
Typical Hold Time | 83 Days | 98 Days |
Enterprise Value | $175.15B | $398.04B |
Dividend Yield | 0.88% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $80.99, down 1.24% on the day, amid a broader market downturn and weak Q3 2026 vehicle sales. The stock shows a bearish technical signal, with key support at $80. Fundamentally, GM's revenue dipped to $185.02B in 2025 with a thin net margin of 1.05%, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights competitive pressure from Toyota and a 5.5% decline in Q3 U.S. sales, driven by EV softness.
GM faces headwinds from declining market share and high debt levels, but analyst consensus remains bullish with a $102.08 price target, implying significant upside. Investment appeal hinges on execution amid industry shifts, while risks include rising borrowing costs and intense competition. Cash flow stability offers some cushion, but profitability recovery is critical for sustained gains.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
